Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2020 | May 07, 2020 | |
Document and Entity Information [Abstract] | ||
Entity Registrant Name | Emerald Bioscience, Inc. | |
Entity Central Index Key | 0001516551 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Common Stock, Shares Outstanding | 183,207,747 | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2020 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q1 | |
Entity Shell Company | false | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Interactive Data Current | Yes |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Current assets | ||
Cash | $ 563,864 | $ 1,829,977 |
Restricted cash | 4,538 | 4,538 |
Prepaid expenses | 99,067 | 152,695 |
Other current assets | 3,888 | 7,550 |
Total current assets | 671,357 | 1,994,760 |
Property and equipment, net | 1,618 | 1,983 |
Total assets | 672,975 | 1,996,743 |
Current liabilities | ||
Accounts payable | 937,266 | 129,809 |
Accounts payable to related party | 40,903 | 10,000 |
Accrued interest due to related party | 35,645 | |
Other current liabilities | 405,344 | 420,406 |
Derivative liabilities | 248,052 | 410,603 |
Total current liabilities | 1,667,210 | 970,818 |
Noncurrent liabilities | ||
Convertible multi-draw credit agreement - related party, net of discount | 517,780 | 387,070 |
Derivative liabilities, non-current | 190,882 | 90,797 |
Total liabilities | 2,375,872 | 1,448,685 |
Commitments and contingencies | ||
Stockholders' (deficit) equity | ||
Preferred stock, $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding at March 31, 2020 and December 31, 2019 | 0 | 0 |
Common stock, $0.001 par value; 500,000,000 shares authorized; 183,207,747 and 182,895,247 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively | 183,208 | 182,895 |
Additional paid-in-capital | 32,628,837 | 32,538,445 |
Accumulated deficit | (34,514,942) | (32,173,282) |
Total stockholders' (deficit) equity | (1,702,897) | 548,058 |
Total liabilities and stockholders' (deficit) equity | $ 672,975 | $ 1,996,743 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares | Mar. 31, 2020 | Dec. 31, 2019 |
Statement Of Financial Position [Abstract] | ||
Preferred stock (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 20,000,000 | 20,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 500,000,000 | 500,000,000 |
Common stock, shares issued | 183,207,747 | 182,895,247 |
Common stock, shares outstanding | 183,207,747 | 182,895,247 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Operating expenses | ||
Research and development | $ 799,612 | $ 320,986 |
General and administrative | 1,411,596 | 1,194,081 |
Total operating expenses | 2,211,208 | 1,515,067 |
Operating loss | (2,211,208) | (1,515,067) |
Other expense (income) | ||
Change in fair value of derivative liabilities | (35,903) | 12,820,618 |
Fair value of derivative liabilities in excess of proceeds | 322,644 | |
Interest expense | 166,355 | 116,063 |
Total other expense, net | 130,452 | 13,259,325 |
Net Loss and comprehensive loss | $ (2,341,660) | $ (14,774,392) |
Loss per common share: | ||
Basic (in dollars per share) | $ (0.01) | $ (0.11) |
Diluted (in dollars per share) | $ (0.01) | $ (0.11) |
Weighted average shares of common stock outstanding used to compute loss per share: | ||
Basic (in shares) | 182,256,966 | 132,729,246 |
Diluted (in shares) | 183,737,415 | 132,729,246 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Cash flows from operating activities: | ||
Net loss | $ (2,341,660) | $ (14,774,392) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation | 365 | 366 |
Stock-based compensation expense | 64,142 | 171,493 |
Change in fair value of derivative liabilities | (35,903) | 12,820,618 |
Fair value of derivative liabilities in excess of proceeds | 0 | 322,644 |
Amortization of debt discount | 130,710 | 56,952 |
Changes in assets and liabilities: | ||
Prepaid expenses | 53,628 | (208,619) |
Other current assets | 3,662 | |
Accounts payable | 807,457 | 152,684 |
Accounts payable to related party | 30,903 | |
Accrued interest due to related party | 35,645 | |
Other current liabilities | (15,062) | 27,134 |
Net cash used in operating activities | (1,266,113) | (1,431,120) |
Cash flows from financing activities: | ||
Proceeds from convertible multi-draw credit agreement - related party, net of issuance costs | 3,990,699 | |
Net cash provided by financing activities | 3,990,699 | |
Net (decrease) increase in cash and restricted cash | (1,266,113) | 2,559,579 |
Cash and restricted cash, beginning of year | 1,834,515 | 1,857,885 |
Cash and restricted cash, end of year | 568,402 | 4,417,464 |
Reconciliation of cash and restricted cash: | ||
Cash | 563,864 | 4,412,952 |
Restricted cash | 4,538 | 4,512 |
Total cash and restricted cash shown in the consolidated statements of cash flows | 568,402 | 4,417,464 |
Cash paid during the year for: | ||
Interest | 59,111 | |
Supplemental disclosures of non-cash financing activities: | ||
Beneficial conversion feature on convertible multi-draw credit agreement | 1,584,850 | |
Proceeds allocated to equity classified warrants issued with convertible multi-draw credit agreement | 716,110 | |
Fair value of compound derivative liability bifurcated from convertible multi-draw credit agreement | $ 193,414 | |
Reclassification of warrant liabilities to equity from exercise of warrants | $ 26,563 |
CONDENSED CONSOLIDATED STATEM_3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($) | Common Stock | Additional Paid-In Capital | Accumulated Deficit | Total |
Balance at Dec. 31, 2018 | $ 133,908 | $ 17,528,947 | $ (33,225,107) | $ (15,562,252) |
Balance (in shares) at Dec. 31, 2018 | 133,907,747 | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Stock-based compensation expense | 171,493 | 171,493 | ||
Warrants issued in connection with convertible multi-draw credit agreement, related party | 716,110 | 716,110 | ||
Beneficial conversion feature in connection with convertible multi-draw credit agreement - related party | 1,584,850 | 1,584,850 | ||
Net loss | (14,774,392) | (14,774,392) | ||
Balance at Mar. 31, 2019 | $ 133,908 | 20,001,400 | (47,999,499) | (27,864,191) |
Balance (in shares) at Mar. 31, 2019 | 133,907,747 | |||
Balance at Dec. 31, 2019 | $ 182,895 | 32,538,445 | (32,173,282) | 548,058 |
Balance (in shares) at Dec. 31, 2019 | 182,895,247 | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Stock-based compensation expense | 64,142 | 64,142 | ||
Series B warrant exercises | $ 313 | 26,250 | 26,563 | |
Series B warrant exercises (in shares) | 312,500 | |||
Net loss | (2,341,660) | (2,341,660) | ||
Balance at Mar. 31, 2020 | $ 183,208 | $ 32,628,837 | $ (34,514,942) | $ (1,702,897) |
Balance (in shares) at Mar. 31, 2020 | 183,207,747 |
Nature of Operations and Busine
Nature of Operations and Business Activities | 3 Months Ended |
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Nature of Operations and Business Activities | 1. Nature of Operations and Business Activities Nature of Operations Emerald Bioscience, Inc. (the “Company”) was initially incorporated in Nevada on March 16, 2011 as Load Guard Logistics, Inc. On October 31, 2014, the Company closed a reverse merger transaction (the “Merger”) pursuant to which Nemus, a California corporation (“Nemus Sub”), became the Company’s wholly-owned subsidiary, and the Company assumed the operations of Nemus Sub. Nemus Sub was incorporated in the State of California on July 17, 2012. On November 3, 2014, the Company changed its name to Nemus Bioscience, Inc. by merging with Nemus Sub. In January 2018, the Company entered into a securities purchase agreement with Emerald Health Sciences, Inc. (“Emerald Health Sciences”), pursuant to which Emerald Health Sciences purchased a majority of the equity interest in the Company, resulting in a change in control (the “Emerald Financing”). As part of the transaction, the Company’s Board members, with the exception of Dr. Brian Murphy, the Company’s CEO/CMO, tendered their resignation and Emerald Health Sciences appointed two new nominees to the Board. Later, in October 2018, the Board appointed Dr. Avtar Dhillon, the Chairman, Chief Executive Officer and President of Emerald Health Sciences, as the Executive Chairman of the Company’s Board. On February 11, 2019, the Company’s Board of Directors (the “Board”) and majority stockholder unanimously approved an amendment to the Company’s articles of incorporation to change the name of the Company to Emerald Bioscience, Inc. Effective March 25, 2019, the Company filed a Certificate of Amendment with the Nevada Secretary of State changing the Company’s name to Emerald Bioscience, Inc. In August 2019, the Company formed a new subsidiary in Australia, EMBI Australia Pty Ltd., an Australian proprietary limited company (“EMBI Australia”), in order to qualify for the Australian government’s research and development tax credit for research and development dollars spent in Australia. The primary purpose of EMBI Australia is to conduct clinical trials for the Company’s product candidates. On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Company’s Board and the Company entered into a Board Observer Agreement with Emerald Health Sciences. Refer to Note 7 - Related Party Matters for additional information. The Company is a biopharmaceutical company located in Long Beach, California that plans to research, develop and commercialize therapeutics derived from cannabinoids through several license agreements with the University of Mississippi (“UM”). UM is the only entity federally permitted and licensed to cultivate cannabis for research purposes in the United States. As of March 31, 2020, the Company has devoted substantially all its efforts to securing product licenses, carrying out research and development, building infrastructure and raising capital. The Company has not yet realized revenue from its planned principal operations and is a number of years from potentially being able to do so. Liquidity and Going Concern The Company has incurred operating losses and negative cash flows from operations since inception and as of March 31, 2020, had an accumulated deficit of $34,514,942, a stockholders’ deficit of $1,702,897 and a working capital deficit of $995,853. $563,864 as compared to $1,829,977 as of December 31, 2019. As the Company approaches its first clinical trial, it expects to ramp up research and development spending and projects to increase cash used in operating activities. However, based on the Company’s current cash position and expected cash requirements, without obtaining additional funding during the second quarter of 2020, management believes that the Company will not have enough funds to meet its current obligations or commence clinical studies. These conditions give rise to substantial doubt as to the Company’s ability to continue as a going concern. The accompanying Condensed Consolidated Financial Statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s continued existence is dependent on its ability to raise sufficient additional funding to cover operating expenses and to invest in research and development activities. On October 5, 2018, the Company entered into a Multi-Draw Credit Agreement (the “Credit Agreement”) with Emerald Health Sciences (See Note 4). On April 29, 2020, the Company entered into an Amended and Restated Multi-Draw Credit Agreement (the “Amended Credit Agreement”) with Emerald Health Sciences, which amends and restates the Credit Agreement. The Amended Credit Agreement provides for a credit facility in the principal amount of up to $20,000,000, which includes, without limitation, the advances totaling $6,000,000 that were granted prior to the amendment and advances of at least $150,000 for each of May, June and July 2020. Prior to the date of the Amended Credit Agreement, the Company had made three drawdowns in an aggregate principal amount of $6,000,000, and had issued to Emerald Health Sciences warrants to purchase an aggregate of 7,500,000 shares of common stock of the Company at an exercise price of $0.50 per share of Common Stock, in accordance with the terms of the Credit Agreement. Immediately upon entering into the Amended Credit Agreement, the Company effected a fourth advance in the amount of $150,000. The advance bears an interest at 7% per annum and matures on October 5, 2022. The Company intends to use the net proceeds of the advance for general corporate and working capital purposes. The Lender has elected that the fourth advance will not be convertible into shares of Common Stock and gave notice to the Company that no warrant will be issued in connection with the advance at this time. On April 22, 2020, the Company entered into a Paycheck Protection Program Promissory Note (the “PPP Note”) in the principal amount of $116,700 (the “PPP Loan”) from City National Bank (the “PPP Loan Lender”). The PPP Loan was obtained pursuant to the Paycheck Protection Program (the “PPP”) of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (“SBA”). Funds from the PPP Loan may only be used by the Company for payroll costs, costs for continuing group healthcare benefits, mortgage interest payments, rent, utility and interest on any other debt obligations that were incurred before February 15, 2020. All or a portion of principal of the PPP Loan may be forgiven by the SBA and the PPP Loan Lender upon application by the Company within 60 days but not later than 120 days after loan approval and upon documentation of expenditures in accordance with the SBA requirements. The Company plans to continue to pursue funding through public or private equity or debt financings, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot provide any assurances that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. Effective March 23, 2020, the Company approved a plan to defer up to 50% of the members of senior management’s compensation indefinitely. Certain members of senior management have accepted the plan and the aggregate deferred compensation, together with a retention bonus of 10% of the amount being deferred will be payable to senior management when decided by the Board. Effective March 30, 2020, the Directors of the Company entered into agreements to defer payment of 100% of their Board of Director and committee fees indefinitely. The accrued fees, plus a 10% bonus of such accrued fees will be payable to the members of the Board within 30 days of the Board of Directors determining that the Company has been sufficiently financed to make such payments. In December 2019, a novel strain of coronavirus (“COVID-19”) emerged in Wuhan, China. Since then, it has spread to the United States and infections have been reported around the world. On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a global pandemic, which continues to spread throughout the United States, Australia and around the world, where the Company has operations and conducts laboratory research and clinical studies. In response to the outbreak, federal and state authorities in the United States have introduced various recommendations and measures to try to limit the pandemic, including travel restrictions, border closures, nonessential business closures, quarantines, self-isolations, shelters-in-place and social distancing. The COVID-19 outbreak and the response of governmental authorities to try to limit it are having a significant impact on the private sector and individuals, including unprecedented business, employment and significant economic disruptions to the global financial markets. These disruptions are likely to impact the Company’s ability to raise additional capital and obtain the necessary funds. Notably, the Company relies on third-party manufacturers to produce its product candidates. The manufacturing of the active pharmaceutical ingredient of NB1111 is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In lieu of the recent pandemic of a COVID-19, there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies. Therefore, the Company has shifted its first-in-human studies of NB1111 from the second half of 2020, to the 2021 timeframe. After considering the plans to alleviate substantial doubt, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies Basis of Presentation In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements have been prepared on a consistent basis with the Company’s Audited Consolidated Financial Statements for the fiscal year ended December 31, 2019, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and therefore, omit certain information and footnote disclosure necessary to present the financial statements in accordance with generally accepted accounting principles in the United States (“GAAP”). The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or any future periods. The Condensed Consolidated Balance Sheet as of December 31, 2019 was derived from the Company’s audited financial statements as of December 31, 2019, which are included in the Company’s Annual Report on Form 10-K filed with the SEC on March 20, 2020. The unaudited financial statements included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which includes a broader discussion of the Company’s business and the risks inherent therein. Certain reclassifications have been made to prior year amounts to conform to the current period’s presentation. Such reclassifications had no net effect on total assets, total liabilities, total stockholders’ equity, net losses and cash flows. Use of Estimates The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities, which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities, and debt with embedded features. Risks and Uncertainties The Company’s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company’s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia, and the Company’s ability to attract new funding. Fair Value Measurements Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the “exit price”) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable, and the last is considered unobservable, is used to measure fair value: Level 1: Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The carrying values of the Company’s financial instruments, with the exception of the Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs. Advances under the Credit Agreement are not recorded at fair value. However, fair value can be approximated and disclosed utilizing Level 3 inputs and independent third-party valuation techniques (See Note 3). As of March 31, 2020 and December 31, 2019, the fair value of the advances under the Credit Agreement was $1,639,245 and $1,877,938, respectively. The carrying amount of the liability at March 31, 2020 and December 31, 2019, was $517,780 and $387,070, respectively, and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company’s Condensed Consolidated Balance Sheets. Convertible Instruments The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815, Derivatives and Hedging Activities The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, Debt with Conversion and Other Options The Company also follows ASC 480-10, Distinguishing Liabilities from Equity When determining the short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments’ exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and makes updates for any changes in facts and circumstances that may impact classification. Warrants Issued in Connection with Financings The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other expense (income) in the Condensed Consolidated Statements of Comprehensive Loss. Debt Issuance Costs and Interest Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions, and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility. Research and Development Expenses and Licensed Technology Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company’s preclinical and clinical drug development activities; facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies. Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date. Stock-Based Compensation Expense Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions: · Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company’s actual stock volatility adjusted for periods in which significant financial variability was identified. · Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award. · Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted. · Dividends - The dividend yield assumption is based on the Company’s history and expectation of paying no dividends in the foreseeable future. Net Income (Loss) Per Share of Common Stock The Company applies FASB ASC No. 260, Earnings per Share Three Months Ended March 31, 2020 2019 Stock options 4,512,715 3,600,073 Unvested restricted stock 643,501 1,093,501 Common shares underlying convertible debt 5,125,363 15,000,000 Warrants 23,593,356 58,130,750 Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12 Income Taxes Recently Adopted Accounting Standards In November 2018, the FASB issued ASU No. 2018-08 Collaborative Arrangements Revenue from Contracts with Customers |
Warrants and Derivative Liabili
Warrants and Derivative Liabilities | 3 Months Ended |
Mar. 31, 2020 | |
Warrants And Derivative Liabilities [Abstract] | |
Warrants and Derivative Liabilities | 3. Warrants and Derivative Liabilities Warrants There are significant judgments and estimates inherent in the determination of the fair value of the Company’s warrants. These judgments and estimates include assumptions regarding the Company’s future operating performance, the time to completing a liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, the fair value of the warrants could have been significantly different (See Note 2). Warrants vested and outstanding as of March 31, 2020 are summarized as follows: Number of Warrants Exercise Term Vested and Source Price (Years) Outstanding Pre 2015 Common Stock Warrants $ 1.00 6—10 4,000,000 2015 Common Stock Warrants $ 1.15-$5.00 5—10 442,000 Common Stock Warrants to Series B Stockholders $ 0.00 5 718,750 2016 Common Stock Warrants to Service Providers $ 1.15 10 40,000 2016 Series C Common Stock Warrants to Placement Agent $ 0.40 5 125,000 2017 Series D Common Stock Warrants to Placement Agent $ 0.25 5 480,000 2017 Common Stock Warrants to Service Provider $ 0.41 5 125,000 2018 Emerald Financing Warrants $ 0.10 5 3,400,000 Emerald Multi Draw Credit Agreement Warrants $ 0.50 5 7,500,000 2019 Common Stock Warrants $ 0.35 5 8,000,000 Total warrants vested and outstanding as of March 31, 2020 24,830,750 Emerald Multi-Draw Credit Agreement Warrants During the three months ended March 31, 2019 , the Company issued 5,000,000 fully vested common stock warrants to Emerald Health Sciences, in conjunction with advances under the Credit Agreement discussed below (See Note 4). The warrants are equity classified at issuance and the Company allocated an aggregate of $716,110 of the gross proceeds to the warrants on a relative fair value basis. The proceeds allocated to the warrants were recorded as discounts to each advance and are being amortized over the term of the debt. The warrants vested immediately and had an estimated aggregate fair value of $1,830,573 utilizing the Black-Scholes Merton option pricing model with the following assumptions: At Dividend yield 0.00 % Volatility factor 91.6 - % Risk-free interest rate 2.23 - % Expected term (years) 5.0 Underlying common stock price $ 0.33—0.69 Derivative Liabilities The following tables summarize the activity of derivative liabilities for the periods indicated: Three Months Ended March 31, 2020 December 31, 2019, Fair Value of Derivative Liabilities Fair Value of Derivative Liabilities Change in Fair value of Liabilities Reclassification of Derivatives to Equity March 31, 2020, Fair Value of Derivative Liabilities Emerald Multi-Draw Credit Agreement - compound derivative liability (1) $ 90,797 $ — $ 100,085 $ — $ 190,882 Emerald Financing - warrant liability (2) 276,024 — (81,879 ) — 194,145 Series B - warrant liability (3) 134,579 — (54,109 ) (26,563 ) 53,907 Total derivative liabilities $ 501,400 $ — $ (35,903 ) $ (26,563 ) $ 438,934 Less, noncurrent portion of derivative liabilities (90,797 ) (190,882 ) Current balance of derivative liabilities $ 410,603 $ 248,052 Three Months Ended March 31, 2019 December 31, 2018, Fair Value of Derivative Liabilities Fair Value of Derivative Liabilities Change in Fair value of Derivative Liabilities Reclassification of Derivatives to Equity March 31, 2019, Fair Value of Derivative Liabilities Emerald Multi-Draw Credit Agreement - compound derivative liability (1) $ 219,453 $ 516,058 $ 227,858 $ — $ 963,369 Emerald Financing - warrant liability (2) 15,251,413 — 12,239,322 — 27,490,735 Series B - warrant liability (3) 487,500 — 353,438 — 840,938 Total derivative liabilities $ 15,958,366 $ 516,058 $ 12,820,618 $ — $ 29,295,042 Less, noncurrent portion of derivative liabilities (219,453 ) (963,369 ) Current balance of derivative liabilities $ 15,738,913 $ 28,331,673 Emerald Multi-Draw Credit Agreement Compound Derivative Liability (1) In connection with the advances under the Credit Agreement (See Note 4), the Company bifurcated a compound derivative liability related to a contingent interest feature and acceleration upon default provision (contingent put option) provided to Emerald Health Sciences. The Company’s estimate of fair value of the compound derivative liability was determined by using a differential cash flows valuation model, wherein the fair value of the underlying debt facility and its conversion right are estimated both with and without the presence of the contingent interest feature, holding all other assumptions constant. The resulting difference between the estimated fair values in both scenarios is the estimated fair value of the compound derivative. The fair value of the underlying debt facility is estimated by calculating the expected cash flows with consideration of the estimated probability of a change in control transaction, defined as an event of default by the agreement, and applying the expected default interest rate from the date of such default through maturity. The expected cash flows are then discounted back to the reporting date using a benchmark market yield. The conversion right component of the compound derivative is measured using a standard Black-Scholes model for each payment period. Because Emerald Health Sciences would forgo the contingent interest if the contingent put option was exercised upon an event of default, the value ascribed to the contingent put option within the compound derivative is de minimis. In determining the fair value of the debt and contingent interest feature the Company used the following assumptions at the balance sheet date: March 31, 2020 Volatility factor 79.8 % Benchmarked yield 18.46 % Remaining term (years) 2.55 Underlying common stock price $ 0.08 Emerald Financing Warrant Liability (2) In January and February 2018, the Company issued 44,200,000 warrants to purchase common stock in conjunction with the Emerald Financing. The warrants vest immediately and have an exercise price of $0.10 per share with a term of five years and are exercisable in cash or through a cashless exercise provision. The warrants contain an anti-dilution protection feature provided to the investors if the Company subsequently issues or sells any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $0.10. The exercise price is automatically adjusted down to the price of the instrument being issued. In addition, the warrants contain a contingent put option if the Company undergoes a subsequent financing that results in a change in control. The warrant holders also have the right to participate in subsequent financing transactions on an as-if converted basis. In December 2019, Emerald Health Sciences paid the aggregate exercise price of $4,080,000 in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement to exercise 40,800,000 Emerald Financing Warrants. Under the Warrant Exercise Agreement between the Company and Emerald Health Sciences, the proceeds from the warrants were first applied directly to the accrued interest balance at the exercise date with the remainder applied to the oldest outstanding principal balances under the Credit Agreement. Immediately prior to exercise, the warrants were adjusted to fair value which considered the closing trading price on the exercise date (See Note 4). The Company reviewed the warrants for liability or equity classification under the guidance of ASC 480-10, Distinguishing Liabilities from Equity Derivatives and Hedging/Contracts in Entity’s Own Equity Fair Value Measurement The warrant liabilities were valued using Monte Carlo simulations conducted at the balance sheet dates using the following assumptions: March 31, 2020 December 31, 2019 Dividend yield 0.00 % 0.00 % Volatility factor 81.4 % 79.5 % Risk-free interest rate 0.28 % 1.62 % Expected term (years) 2.88 3.13 Underlying common stock price $ 0.08 $ 0.13 Series B Warrant Liability (3) In conjunction with the Redeemable Convertible Series B Preferred Stock financing, the Company issued the 2015 Series B Financing Warrants originally exercisable at a price of $1.15 per share. The warrants are exercisable in cash or through a cashless exercise provision and contain certain cash redemption rights. The Series B warrants also had a “down-round” protection feature if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the current exercise price. The down round provision was triggered and automatically adjusted down to $0.10 on December 28, 2017, after the Company entered into the Convertible Promissory Note (See Note 4) and again to $0.00 on January 19, 2018, as a result of the Emerald Financing. The strike price for these warrants is now permanently reset. However, because the remaining warrant holders still have certain cash redemption rights upon the occurrence of certain fundamental transactions, as defined in the Series B warrant agreements, the warrants continue to require liability classification. Subsequent to the repricing that occurred as a result of the Emerald Financing, the warrants have been valued using a Black Scholes Merton Option Pricing Model. To compute the fair value of the warrants, the Company utilized the following assumptions in the Black Scholes Merton Option Pricing Model for the periods indicated: As of March 31, 2020 As of December 31, 2019 Dividend yield 0.00 % 0.00 % Volatility factor 79.8 % 79.2 % Risk-free interest rate 0.13 % 1.60 % Expected term (years) 0.39 0.64 Underlying common stock price $ 0.08 $ 0.13 During the three months ended March 31, 2020, 312,500 Series B Common Stock Warrants with an intrinsic value of $26,563 were exercised for no consideration per share, which resulted in the issuance of 312,500 shares of common stock. Prior to exercise, these Series B Warrants were adjusted to fair value using a Black Scholes Merton Option Pricing Model which considered the closing trading price on the exercise dates. Because the exercise price of these options had been reset to $0.00, the fair value derived from the valuation model approximated the market value of the Company’s common stock on the exercise dates. |
Convertible Debt - Related Part
Convertible Debt - Related Party | 3 Months Ended |
Mar. 31, 2020 | |
Debt Disclosure [Abstract] | |
Convertible Debt - Related Party | 4. Convertible Debt - Related Party The Company’s Convertible Debt with Emerald Health Sciences consists of the following: As of March 31, 2020 As of December 31, 2019 Total principal value $ 2,014,500 $ 2,014,500 Unamortized debt discount (1,491,997 ) (1,622,344 ) Unamortized debt issuance costs (4,723 ) (5,086 ) Carrying value of total convertible debt - related party $ 517,780 $ 387,070 Less, noncurrent portion (517,780 ) (387,070 ) Current convertible debt - related party $ — $ — The Company’s interest expense consists of the following: Three Months Ended March 31, 2020 2019 Interest expense - stated rate $ 35,645 $ 59,111 Non-cash interest expense: Amortization of debt discount 130,347 53,979 Amortization of transaction costs 363 2,973 $ 166,355 $ 116,063 Multi-Draw Credit Agreement On October 5, 2018, the Company entered into the Credit Agreement with Emerald Health Sciences, a related party (See Note 7). The Credit Agreement provides for a credit facility to the Company of up to $20,000,000 and is unsecured. Advances under the Credit Agreement bear interest at an annual rate of 7% (payable quarterly in arrears) and mature on October 5, 2022. At Emerald Health Sciences’ election, advances and unpaid interest may be converted into common stock at a fixed conversion price of $0.40, subject to customary adjustments for stock splits, stock dividends, recapitalizations, etc. As of March 31, 2020, the unused portion of the credit facility is $14,000,000. The drawdowns are subject to approval by the Company’s Board, which is controlled by the directors of Emerald Health Sciences. As such, we do not consider the facility available until advance requests are approved, drawn down and funded. The Credit Agreement is still in place, however, there is no guarantee of continued funding. The Credit Agreement provides for customary events of default which may result in the acceleration of the maturity of the advances in addition to, but not limited to, cross acceleration to certain other indebtedness of the Company or a change in control. In the case of an event of default arising from specified events of bankruptcy or insolvency or reorganization, all outstanding advances will become due and payable immediately without further action or notice. If any other event of default under the Credit Agreement occurs or is continuing, Emerald Health Sciences may, by written notice, terminate its commitment to make any advances and/or declare all the advances with any other amounts payable due immediately. If any amount under the Credit Agreement is not paid when due, such overdue amount shall bear interest at an annual default interest rate of the applicable rate plus 10%, until such amount is paid in full. In connection with each advance under the Credit Agreement, the Company agreed to issue to Emerald Health Sciences warrants to purchase shares of common stock in an amount equal to 50% of the number of shares of common stock that each advance may be converted into. The warrants have an exercise price of $0.50 per share, a term of five years and are immediately exercisable upon issuance. The exercise price is subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events or upon any distributions of assets, including cash, stock or other property to the Company’s stockholders (See Note 3). In accounting for each convertible advance and the warrants issued under the Credit Agreement, the Company allocates the proceeds between the debt host and the freestanding warrants on a relative fair value basis for each advance. On the date of each advance, if the effective conversion rate of the debt is less than the market value of the Company’s common stock, the Company records a beneficial conversion feature as a discount to the debt and an increase to additional paid-in capital. The debt discounts related to the warrants, beneficial conversion features and compound derivatives, if any, are being amortized over the term of the Credit Agreement using the effective interest rate method. Amortization of the debt discount is recognized as non-cash interest expense and the compound derivatives related to the contingent interest feature and acceleration upon default provision are remeasured at fair value in subsequent periods in the Company’s Condensed Consolidated Balance Sheets. On November 1, 2018, the initial advance under Credit Agreement was made for $2,000,000 and the Company issued 2,500,000 warrants (See Note 3). In accounting for the convertible advances and warrants under the Credit Agreement, $1,684,920 of the proceeds was allocated to the debt and $315,080 was allocated to equity classified warrants. A beneficial conversion feature of $90,080 and a compound derivative liability of $204,102 were also recorded. During the three months ended March 31, 2019, the Company initiated two advances under Credit Agreement, each in the amount of $2,000,000, for an aggregate principal amount of $4,000,000, and the Company issued an aggregate of 5,000,000 warrants to Emerald Health Sciences (See Note 3). In accounting for the convertible advances and warrants issued under the Credit Agreement, an aggregate amount of $3,283,890 was allocated to the debt and $716,110 was allocated to equity classified warrants. A beneficial conversion feature of $1,584,850 and compound derivative liabilities of an aggregate of $516,058 have been recorded (See Note 3). Of the $516,058 in compound derivatives, $322,644 was recorded as other expense in the Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2019, as the value of the beneficial conversion feature exceeded the proceeds allocated to the third draw. Aggregate financing costs of $63,007 incurred in connection with the Credit Agreement have been recorded as a discount to the debt host and are being amortized using the effective interest rate method and recognized as non-cash interest expense over the term of the Credit Agreement. During the year ended December 31, 2019, the Company used $3,985,500 in proceeds from the exercise of the 2018 Emerald Financing Warrants to prepay a portion of the principal balance on the Credit Agreement. In connection with the prepayment, the Company recorded an extinguishment loss of $725,425 in the fourth quarter of 2019. The extinguishment loss was calculated as the difference between the fair value of the consideration paid to extinguish the debt and carrying value of the debt host plus the related compound derivative liability. As of March 31, 2020, the unamortized debt discount will be amortized over a remaining period of approximately 2.52 years. The fair value of the underlying shares of the convertible multi draw credit agreement was $377,719 at March 31, 2020. As of March 31, 2020, the if-converted value did not exceed the principal balance. |
Stock-Based Compensation
Stock-Based Compensation | 3 Months Ended |
Mar. 31, 2020 | |
Share-based Payment Arrangement [Abstract] | |
Stock-Based Compensation | 5. Stock-Based Compensation Stock Incentive Plan On October 31, 2014, after the closing of the Merger, the Board approved the Company’s 2014 Omnibus Incentive Plan (the “2014 Plan”). The 2014 Plan initially reserved 3,200,000 shares for future grants. In October 2018, the Company increased the share reserve under the 2014 Plan to equal 10% of the number of issued and outstanding shares of common stock of the Company. The 2014 Plan authorizes the issuance of awards including stock options, stock appreciation rights, restricted stock, stock units and performance units to employees, directors, and consultants of the Company. As of March 31, 2020, the Company had 13,159,631 shares available for future grant under the 2014 Plan. Stock Options There was no option activity under the Company’s 2014 Plan during the three months ended March 31, 2020. Restricted Stock Awards There was no restricted stock award (“RSA”) activity under the Company’s 2014 Plan during the three months ended March 31, 2020. Awards Granted Outside the 2014 Plan Options There was no option activity outside of the 2014 Plan during the three months ended March 31, 2020. Restricted Stock Awards The following is a summary of RSA activity outside of the Company’s 2014 Plan during the three months ended March 31, 2020: Number of Shares Weighted Average Grant Date Fair Value Unvested, December 31, 2019 450,000 $ 0.19 Granted — — Released (450,000 ) 0.19 Unvested, March 31, 2020 — $ — Stock-Based Compensation Expense The Company recognizes compensation expense using the straight-line method over the requisite service period. For the three months ended March 31, 2020 and 2019, the Company recognized stock-based compensation expense of $64,142 and $171,493, respectively (including compensation expense for RSAs discussed above), which was recorded as a general and administrative expense in the Condensed Consolidated Statements of Comprehensive Loss. The total amount of unrecognized compensation cost was $248,264 as of March 31, 2020. This amount will be recognized over a weighted average period of 1.74 years. |
Significant Contracts - Univers
Significant Contracts - University of Mississippi | 3 Months Ended |
Mar. 31, 2020 | |
Significant Contracts [Abstract] | |
Significant Contracts - University of Mississippi | 6. Significant Contracts - University of Mississippi UM 5050 Pro-Drug and UM 8930 Analog Agreements In July 2018, the Company renewed its ocular licenses for UM 5050, related to the pro-drug formulation of tetrahydrocannabinol (“THC”), and UM 8930, related to an analog formulation of cannabidiol (“CBD”). On May 24, 2019, the ocular delivery licenses were replaced by “all fields of use” licenses for both UM 5050 and UM 8930 (collectively, the “License Agreements”). Pursuant to the License Agreements, UM granted the Company an exclusive, perpetual license, including, with the prior written consent of UM, the right to sublicense, to intellectual property related to UM 5050 and UM 8930 for all fields of use. The License Agreements contain certain milestone payments, royalty and sublicensing fees payable by the Company, as defined therein. Each License Agreement provides for an annual maintenance fee of $75,000 payable on the anniversary of the effective date. The upfront payment for UM 5050 is $100,000 and the upfront payment for UM 8930 is $200,000. In addition, in March 2020, the Company was notified by the United States Patent and Trademark Office, that a notice of allowance was issued for the proprietary analog of cannabidiol, CBDVHS, under the UM 8930 License Agreement. As a result, the Company was required to pay UM a fee of $200,000. The milestone payments payable for each license are as follows: i) $100,000 paid within 30 days following the submission of the first Investigational New Drug Application to the Food and Drug Administration or an equivalent application to a regulatory agency anywhere in the world, for a product; ii) $200,000 paid within 30 days following the first submission of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early submitted product(s); and iii) $400,000 paid within 30 days following the approval of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early approved product(s). The royalty percentage due on net sales under each License Agreement is in the mid-single digits. The Company must also pay to UM a portion of all licensing fees received from any sublicensees, subject to a minimum royalty on net sales, and the Company is required to reimburse patent costs incurred by UM related to the licensed products. The royalty obligations apply by country and by licensed product, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after the first commercial sale of such licensed product in such country. Each License Agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or the expiration of the Company’s payment obligations under such License Agreement. UM may terminate each License Agreement, by giving written notice of termination, upon the Company’s material breach of such License Agreement, including failure to make payments or satisfy covenants, representations or warranties without cure, noncompliance, a bankruptcy event, the Company’s dissolution or cessation of operations, the Company’s failure to make reasonable efforts to commercialize at least one product or failure to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside the Company’s control, or the Company’s failure to meet certain pre-established development milestones. The Company may terminate each License Agreement upon 60 days’ written notice to UM. As of March 31, 2020, with the exception of the fee due for the notice of allowance for CBDVHS, none of the other milestones under these license agreements have been met. UM 5070 License Agreement In January 2017, the Company entered into a license agreement with UM pursuant to which UM granted us an exclusive, perpetual license, including the right to sublicense, to intellectual property related to a platform of cannabinoid-based molecules (“UM 5070”), to research, develop and commercialize products for the treatment of infectious diseases. The license agreement culminates roughly one year of screening and target molecule identification studies especially focused on therapy-resistant infectious organisms like Methicillin-resistant Staphylococcus aureus (“MRSA”). The Company paid UM an upfront license fee under the license agreement. Under the license agreement, the Company is also responsible for annual maintenance fees that will be credited against royalties in the current fiscal year, contingent milestone payments upon achievement of development and regulatory milestones, and royalties on net sales of licensed products sold for commercial use. The aggregate milestone payments due under the license agreement if all the milestones are achieved is $700,000 and the royalty percentage due on net sales is in the mid-single digits. The Company must also pay to UM a percentage of all licensing fees we receive from any sublicensees, subject to a minimum royalty on net sales by such sublicensees. The Company’s royalty obligations apply on a country by country and licensed product by licensed product basis, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after first commercial sale of such licensed product in such country. The license agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or expiration of the Company’s payment obligations under the license. UM may terminate the license agreement, effective with the giving of notice, if: (a) the Company fails to pay any material amount payable to UM under the license agreement and do not cure such failure within 60 days after UM notifies us of such failure, (b) the Company materially breaches any covenant, representation or warranty in the license agreement and do not cure such breach within 60 days after UM notifies the Company of such breach, (c) the Company fails to comply in any material respect with the terms of the license and do not cure such noncompliance within 60 days after UM notifies us of such failure, (d) the Company is subject to a bankruptcy event, (e) the Company dissolves or ceases operations or (f) if after the first commercial sale of a product during the term of the license agreement, the Company materially fails to make reasonable efforts to commercialize at least one product or fail to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside of the Company’s control. The Company may terminate the license agreement upon 60 days’ written notice to UM. As of March 31, 2020, none of the milestones under this license agreement have been met. |
Related Party Matters
Related Party Matters | 3 Months Ended |
Mar. 31, 2020 | |
Related Party Transactions [Abstract] | |
Related Party Matters | 7. Related Party Matters Emerald Health Sciences On February 1, 2018, the Company entered into an Independent Contractor Agreement with Emerald Health Sciences, pursuant to which Emerald Health Sciences agreed to provide such services as are mutually agreed between the Company and Emerald Health Sciences, including reimbursement for reasonable expenses incurred in the performance of the Independent Contractor Agreement. These services included, but were not limited to, corporate advisory services and technical expertise in the areas of business development, marketing, investor relations, information technology and product development. The Independent Contractor Agreement had an initial term of 10 years and specified compensation which was agreed upon between the Company’s Chief Executive Officer and Emerald Health Sciences’ Chairman, CEO and President on a month-to-month basis. The fee due under this agreement was payable on a monthly basis. Effective December 31, 2019, the Independent Contractor Agreement was terminated. As of March 31, 2020, the Company maintains an accrual of $7,032 in expenses under the Independent Contractor Agreement which have yet to be paid. Under this agreement, no expenses were incurred for the three months ended March 31, 2020. For the three months ended March 31, 2019, the Company incurred expenses of $150,000. On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Board and the position of Chairman of the Finance and Business Development Committee of the Board. Concurrently, the Company entered into a Board Observer Agreement with Emerald Health Sciences to allow Dr. Dhillon to continue as a representative of Emerald Health Sciences as a non-voting observer in future meetings of the Board. On December 19, 2019, the Company entered into an Independent Contractor Services Agreement with Dr. Avtar Dhillon, pursuant to which Dr. Dhillon will provide ongoing corporate finance and strategic business advisory services to the Company. In exchange for his services, Dr. Dhillon will receive a monthly fee of $10,000, with (i) $5,000 paid each month and (ii) $5,000 accruing from the effective date and payable upon the Company’s completion of a material financing. The Board will review the monthly rate paid to Dr. Dhillon within 90 days of the end of each fiscal year. The Independent Contractor Services Agreement has an initial term of one year and will renew automatically thereafter unless terminated earlier by either party. The Independent Contractor Services Agreement may be terminated by either party for cause upon written notice to the other party if the other party defaults in the performance of the agreement in any material respect or materially breaches the terms of the agreement, or without cause upon 30 days’ prior written notice to the other party. On March 30, 2020, the Company and Dr. Dhillon amended the Independent Contractor Services Agreement by agreeing to accrue 100% of Dr. Dhillon’s consulting fees until the Board of Directors determines that the Company has been sufficiently financed to make such payments at which point the Company agrees to pay Dr. Dhillon all of his accrued consulting fees, and a bonus of 10% of his accrued consulting fees, less applicable tax and other withholdings. As of March 31, 2020, the Company has accrued $33,871 in expense related to the Independent Contractor Services Agreement. |
Subsequent Events
Subsequent Events | 3 Months Ended |
Mar. 31, 2020 | |
Subsequent Events [Abstract] | |
Subsequent Events | 8. Subsequent Events Amended and Restated Multi-Draw Credit Agreement On April 29, 2020, the Company entered into an Amended and Restated Multi-Draw Credit Agreement with Emerald Health Sciences, which amends and restates the Credit Agreement, dated October 5, 2018. The Amended Credit Agreement provides for a credit facility in the principal amount of up to $20,000,000, which includes, without limitation, the advances totaling $6,000,000 that were granted prior to the amendment and advances of at least $150,000 for each of May, June and July 2020. In connection with each advance under the Amended Credit Agreement, the Company shall, absent the Lender’s notice not to issue any warrant, continue to issue to Emerald Health Sciences, a warrant to purchase up to the number of shares of the Common Stock of the Company equal to the dollar amount of such advance divided by 0.50. However, warrants issued under the Amended Credit Agreement will have an exercise price of $0.35 per share of Common Stock. Warrants issued prior to the date of the Amended Credit Agreement shall not be modified, amended or altered by the terms of the Amended Credit Agreement and shall remain in full force and effect. Emerald Health Science will, in its sole discretion, at the time of an advance, determine as to whether such advance will or will not be convertible into shares of Common Stock in the future. Advances under the Amended Credit Agreement are convertible into shares of Common Stock at a reduced fixed conversion price of $0.25 per share of Common Stock. However, the conversion price of all advances outstanding under the Credit Agreement as of the date of the Amended Credit Agreement shall be deemed convertible by the Lender at a conversion price of $0.40 per share of Common Stock as set forth in the Existing Credit Agreement. Pursuant to the Amended Credit Agreement, the Company and the Lender have agreed to terminate that certain Registration Rights Agreement, dated as of October 5, 2018, by and between the Company and the Lender, and the Lender has agreed to defer all interest accrued and/or due under the Amended Credit Agreement, beginning the quarter ended June 30, 2020, until the Company completes a capital raise of at least $5,000,000. All other material terms of the Credit Agreement, including, without limitation, the maturity date and interest rate, remain the same in the Amended Credit Agreement. Immediately upon entering into the Amended Credit Agreement, the Company effected a fourth advance in the amount of $150,000. The advance bears an interest at 7% per annum and matures on October 5, 2022. The Company intends to use the net proceeds of the advance for general corporate and working capital purposes. The Lender has elected that the fourth advance will not be convertible into shares of Common Stock and gave notice to the Company that no warrant will be issued in connection with the advance at this time. Paycheck Protection Program Promissory Note On April 22, 2020, the Company entered into a PPP Note in the principal amount of $116,700 from the PPP Loan Lender. The PPP Loan was obtained pursuant to the PPP of the CARES Act administered by the SBA. The PPP Loan was disbursed by the PPP Loan Lender to the Company on April 24, 2020 and will mature two years from the Disbursement Date. The PPP Loan bears an interest at 1.00% per annum and is payable monthly commencing seven months from the Disbursement Date. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the PPP Loan may only be used by the Company for payroll costs, costs for continuing group healthcare benefits, mortgage interest payments, rent, utility and interest on any other debt obligations that were incurred before February 15, 2020. All or a portion of principal of the PPP Loan may be forgiven by the SBA and the PPP Loan Lender upon application by the Company within 60 days but not later than 120 days after loan approval and upon documentation of expenditures in accordance with the SBA requirements. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, and covered utilities during the eight-week period commencing on the date of loan approval. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $100,000, prorated annually. Not more than 25% of the forgiveness amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages of employees with salaries of $100,000 or less annually are reduced by more than 25%. After approval of the forgiveness amount and six month deferral period, the PPP Loan Lender will provide the Company with written notification of re-amortization of the PPP Loan and the remaining balance. Separation of Chief Financial Officer On April 29, 2020, the Company entered into a separation and release agreement (the “Separation Agreement”) with Douglas Cesario, Chief Financial Officer. Mr. Cesario’s separation will be effective May 15, 2020 (the “Separation Date”), and he will remain the Company’s principal financial officer until the Separation Date. Pursuant to the Separation Agreement, Mr. Cesario has agreed to certain ongoing cooperation obligations and to provide certain releases and waivers as contained in the Separation Agreement. As consideration under the Separation Agreement, the Company has agreed to provide Mr. Cesario compensation and benefits as follows: (i) through the Separation Date, an annualized base salary at the rate in effect for him as of the date of the Separation Agreement; (ii) a gross payment of $125,000 in consideration for the restrictive covenants contained in the Separation Agreement; and (iii) a continuation of health insurance benefits for a period of six months following the Separation Date. In connection with the termination of the Company’s Chief Financial Officer 325,929 unvested stock options will be cancelled on May 15, 2020. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements have been prepared on a consistent basis with the Company’s Audited Consolidated Financial Statements for the fiscal year ended December 31, 2019, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and therefore, omit certain information and footnote disclosure necessary to present the financial statements in accordance with generally accepted accounting principles in the United States (“GAAP”). The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or any future periods. The Condensed Consolidated Balance Sheet as of December 31, 2019 was derived from the Company’s audited financial statements as of December 31, 2019, which are included in the Company’s Annual Report on Form 10-K filed with the SEC on March 20, 2020. The unaudited financial statements included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which includes a broader discussion of the Company’s business and the risks inherent therein. Certain reclassifications have been made to prior year amounts to conform to the current period’s presentation. Such reclassifications had no net effect on total assets, total liabilities, total stockholders’ equity, net losses and cash flows. |
Use of Estimates | Use of Estimates The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities, which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities, and debt with embedded features. |
Risks and Uncertainties | Risks and Uncertainties The Company’s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company’s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia, and the Company’s ability to attract new funding. |
Fair Value Measurements | Fair Value Measurements Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the “exit price”) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable, and the last is considered unobservable, is used to measure fair value: Level 1: Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The carrying values of the Company’s financial instruments, with the exception of the Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs. Advances under the Credit Agreement are not recorded at fair value. However, fair value can be approximated and disclosed utilizing Level 3 inputs and independent third-party valuation techniques (See Note 3). As of March 31, 2020 and December 31, 2019, the fair value of the advances under the Credit Agreement was $1,639,245 and $1,877,938, respectively. The carrying amount of the liability at March 31, 2020 and December 31, 2019, was $517,780 and $387,070, respectively, and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company’s Condensed Consolidated Balance Sheets. |
Convertible Instruments | Convertible Instruments The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815, Derivatives and Hedging Activities The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, Debt with Conversion and Other Options The Company also follows ASC 480-10, Distinguishing Liabilities from Equity When determining the short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments’ exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and makes updates for any changes in facts and circumstances that may impact classification. |
Warrants Issued in Connection with Financings | Warrants Issued in Connection with Financings The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other expense (income) in the Condensed Consolidated Statements of Comprehensive Loss. |
Debt Issuance Costs and Interest | Debt Issuance Costs and Interest Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions, and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility. |
Research and Development Expenses and Licensed Technology | Research and Development Expenses and Licensed Technology Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company’s preclinical and clinical drug development activities; facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies. Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date. |
Stock-Based Compensation Expense | Stock-Based Compensation Expense Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions: · Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company’s actual stock volatility adjusted for periods in which significant financial variability was identified. · Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award. · Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted. · Dividends - The dividend yield assumption is based on the Company’s history and expectation of paying no dividends in the foreseeable future. |
Net Income (Loss) Per Share of Common Stock | Net Income (Loss) Per Share of Common Stock The Company applies FASB ASC No. 260, Earnings per Share Three Months Ended March 31, 2020 2019 Stock options 4,512,715 3,600,073 Unvested restricted stock 643,501 1,093,501 Common shares underlying convertible debt 5,125,363 15,000,000 Warrants 23,593,356 58,130,750 |
Recent Accounting Pronouncements | Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12 Income Taxes Recently Adopted Accounting Standards In November 2018, the FASB issued ASU No. 2018-08 Collaborative Arrangements Revenue from Contracts with Customers |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Schedule of outstanding shares of common stock equivalents were excluded from the computation of diluted earnings per share | Three Months Ended March 31, 2020 2019 Stock options 4,512,715 3,600,073 Unvested restricted stock 643,501 1,093,501 Common shares underlying convertible debt 5,125,363 15,000,000 Warrants 23,593,356 58,130,750 |
Warrants and Derivative Liabi_2
Warrants and Derivative Liabilities (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Derivative Liabilities Line Items | |
Schedule of warrants vested and outstanding | Number of Warrants Exercise Term Vested and Source Price (Years) Outstanding Pre 2015 Common Stock Warrants $ 1.00 6—10 4,000,000 2015 Common Stock Warrants $ 1.15-$5.00 5—10 442,000 Common Stock Warrants to Series B Stockholders $ 0.00 5 718,750 2016 Common Stock Warrants to Service Providers $ 1.15 10 40,000 2016 Series C Common Stock Warrants to Placement Agent $ 0.40 5 125,000 2017 Series D Common Stock Warrants to Placement Agent $ 0.25 5 480,000 2017 Common Stock Warrants to Service Provider $ 0.41 5 125,000 2018 Emerald Financing Warrants $ 0.10 5 3,400,000 Emerald Multi Draw Credit Agreement Warrants $ 0.50 5 7,500,000 2019 Common Stock Warrants $ 0.35 5 8,000,000 Total warrants vested and outstanding as of March 31, 2020 24,830,750 |
Schedule of the activity of derivative liabilities | Three Months Ended March 31, 2020 December 31, 2019, Fair Value of Derivative Liabilities Fair Value of Derivative Liabilities Change in Fair value of Liabilities Reclassification of Derivatives to Equity March 31, 2020, Fair Value of Derivative Liabilities Emerald Multi-Draw Credit Agreement - compound derivative liability (1) $ 90,797 $ — $ 100,085 $ — $ 190,882 Emerald Financing - warrant liability (2) 276,024 — (81,879 ) — 194,145 Series B - warrant liability (3) 134,579 — (54,109 ) (26,563 ) 53,907 Total derivative liabilities $ 501,400 $ — $ (35,903 ) $ (26,563 ) $ 438,934 Less, noncurrent portion of derivative liabilities (90,797 ) (190,882 ) Current balance of derivative liabilities $ 410,603 $ 248,052 Three Months Ended March 31, 2019 December 31, 2018, Fair Value of Derivative Liabilities Fair Value of Derivative Liabilities Change in Fair value of Derivative Liabilities Reclassification of Derivatives to Equity March 31, 2019, Fair Value of Derivative Liabilities Emerald Multi-Draw Credit Agreement - compound derivative liability (1) $ 219,453 $ 516,058 $ 227,858 $ — $ 963,369 Emerald Financing - warrant liability (2) 15,251,413 — 12,239,322 — 27,490,735 Series B - warrant liability (3) 487,500 — 353,438 — 840,938 Total derivative liabilities $ 15,958,366 $ 516,058 $ 12,820,618 $ — $ 29,295,042 Less, noncurrent portion of derivative liabilities (219,453 ) (963,369 ) Current balance of derivative liabilities $ 15,738,913 $ 28,331,673 |
Emerald Multi-Draw Credit Agreement Warrants | |
Derivative Liabilities Line Items | |
Schedule of input and valuation technique used to value derivative liabilities | At Dividend yield 0.00 % Volatility factor 91.6 - % Risk-free interest rate 2.23 - % Expected term (years) 5.0 Underlying common stock price $ 0.33—0.69 |
Emerald Multi-Draw Credit Agreement Compound Derivative Liability | |
Derivative Liabilities Line Items | |
Schedule of input and valuation technique used to value derivative liabilities | March 31, 2020 Volatility factor 79.8 % Benchmarked yield 18.46 % Remaining term (years) 2.55 Underlying common stock price $ 0.08 |
Emerald Financing Warrant Liability | |
Derivative Liabilities Line Items | |
Schedule of input and valuation technique used to value warrant liabilities | March 31, 2020 December 31, 2019 Dividend yield 0.00 % 0.00 % Volatility factor 81.4 % 79.5 % Risk-free interest rate 0.28 % 1.62 % Expected term (years) 2.88 3.13 Underlying common stock price $ 0.08 $ 0.13 |
Series B Warrant Liability | |
Derivative Liabilities Line Items | |
Schedule of input and valuation technique used to value warrant liabilities | As of March 31, 2020 As of December 31, 2019 Dividend yield 0.00 % 0.00 % Volatility factor 79.8 % 79.2 % Risk-free interest rate 0.13 % 1.60 % Expected term (years) 0.39 0.64 Underlying common stock price $ 0.08 $ 0.13 |
Convertible Debt - Related Pa_2
Convertible Debt - Related Party (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Debt Disclosure [Abstract] | |
Schedule of convertible debt | As of March 31, 2020 As of December 31, 2019 Total principal value $ 2,014,500 $ 2,014,500 Unamortized debt discount (1,491,997 ) (1,622,344 ) Unamortized debt issuance costs (4,723 ) (5,086 ) Carrying value of total convertible debt - related party $ 517,780 $ 387,070 Less, noncurrent portion (517,780 ) (387,070 ) Current convertible debt - related party $ — $ — |
Schedule of interest expense | Three Months Ended March 31, 2020 2019 Interest expense - stated rate $ 35,645 $ 59,111 Non-cash interest expense: Amortization of debt discount 130,347 53,979 Amortization of transaction costs 363 2,973 $ 166,355 $ 116,063 |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Share-based Payment Arrangement [Abstract] | |
Schedule of RSA activity | Number of Shares Weighted Average Grant Date Fair Value Unvested, December 31, 2019 450,000 $ 0.19 Granted — — Released (450,000 ) 0.19 Unvested, March 31, 2020 — $ — |
Nature of Operations and Busi_2
Nature of Operations and Business Activities (Detail Textuals) - USD ($) | 1 Months Ended | ||||||||||
Jul. 31, 2020 | Jun. 30, 2020 | May 31, 2020 | May 11, 2020 | Apr. 29, 2020 | Mar. 23, 2020 | Apr. 22, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Mar. 31, 2019 | Dec. 31, 2018 | |
Nature Of Operations And Business Activities [Line Items] | |||||||||||
Accumulated deficit | $ (34,514,942) | $ (32,173,282) | |||||||||
Stockholders' deficit | (1,702,897) | 548,058 | $ (27,864,191) | $ (15,562,252) | |||||||
Working capital deficit | (995,853) | ||||||||||
Cash and cash equivalents | $ 563,864 | $ 1,829,977 | |||||||||
Description of senior management's compensation plan | Effective March 23, 2020, the Company approved a plan to defer up to 50% of the members of senior management’s compensation indefinitely. Certain members of senior management have accepted the plan and the aggregate deferred compensation, together with a retention bonus of 10% of the amount being deferred will be payable to senior management when decided by the Board. Effective March 30, 2020, the Directors of the Company entered into agreements to defer | ||||||||||
Subsequent Event | |||||||||||
Nature Of Operations And Business Activities [Line Items] | |||||||||||
Unrestricted cash position decreased | $ 228,000 | ||||||||||
Additional of restricted cash | 87,000 | ||||||||||
Remaining funds from promissory note | $ 82,000 | ||||||||||
Subsequent Event | Paycheck Protection Program Promissory Note (PPP Note) | |||||||||||
Nature Of Operations And Business Activities [Line Items] | |||||||||||
Principal amount of promissory Note | $ 116,700 | ||||||||||
Amended and Restated Multi-Draw Credit Agreement | Subsequent Event | |||||||||||
Nature Of Operations And Business Activities [Line Items] | |||||||||||
Principal amount of credit facility | $ 20,000,000 | ||||||||||
Credit facility advances | 6,000,000 | ||||||||||
Credit facility advances per month | $ 150,000 | $ 150,000 | $ 150,000 | ||||||||
Draw downs loans In aggregate principal amount | $ 6,000,000 | ||||||||||
Warrants to purchase an aggregate shares of common stock | 7,500,000 | ||||||||||
Exercise Price | $ 0.50 | ||||||||||
Interest rates per annum | 7.00% | ||||||||||
Maturity date | Oct. 5, 2022 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies (Details) - shares | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Warrants | ||
Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items] | ||
Anti-dilutive excluded from the calculation of diluted loss per common share | 23,593,356 | 58,130,750 |
Common shares underlying convertible debt | ||
Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items] | ||
Anti-dilutive excluded from the calculation of diluted loss per common share | 5,125,363 | 15,000,000 |
Stock options | ||
Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items] | ||
Anti-dilutive excluded from the calculation of diluted loss per common share | 4,512,715 | 3,600,073 |
Unvested restricted stock | ||
Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items] | ||
Anti-dilutive excluded from the calculation of diluted loss per common share | 643,501 | 1,093,501 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies (Detail Textuals) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Accounting Policies [Abstract] | ||
Fair value of advance under credit agreement | $ 1,639,245 | $ 1,877,938 |
Carrying value of total convertible debt - related party | $ 517,780 | $ 387,070 |
Warrants and Derivative Liabi_3
Warrants and Derivative Liabilities (Details) | 3 Months Ended |
Mar. 31, 2020$ / sharesshares | |
Class of Warrant or Right [Line Items] | |
Amount Vested and Outstanding | shares | 24,830,750 |
Pre 2015 Common Stock Warrants | |
Class of Warrant or Right [Line Items] | |
Exercise Price | $ / shares | $ 1 |
Amount Vested and Outstanding | shares | 4,000,000 |
Pre 2015 Common Stock Warrants | Minimum | |
Class of Warrant or Right [Line Items] | |
Term (Years) | 6 years |
Pre 2015 Common Stock Warrants | Maximum | |
Class of Warrant or Right [Line Items] | |
Term (Years) | 10 years |
2015 Common Stock Warrants | |
Class of Warrant or Right [Line Items] | |
Amount Vested and Outstanding | shares | 442,000 |
2015 Common Stock Warrants | Minimum | |
Class of Warrant or Right [Line Items] | |
Exercise Price | $ / shares | $ 1.15 |
Term (Years) | 5 years |
2015 Common Stock Warrants | Maximum | |
Class of Warrant or Right [Line Items] | |
Exercise Price | $ / shares | $ 5 |
Term (Years) | 10 years |
Common Stock Warrants to Series B Stockholders | |
Class of Warrant or Right [Line Items] | |
Exercise Price | $ / shares | $ 0 |
Term (Years) | 5 years |
Amount Vested and Outstanding | shares | 718,750 |
2016 Common Stock Warrants to Service Providers | |
Class of Warrant or Right [Line Items] | |
Exercise Price | $ / shares | $ 1.15 |
Term (Years) | 10 years |
Amount Vested and Outstanding | shares | 40,000 |
2016 Series C Common Stock Warrants to Placement Agent | |
Class of Warrant or Right [Line Items] | |
Exercise Price | $ / shares | $ 0.40 |
Term (Years) | 5 years |
Amount Vested and Outstanding | shares | 125,000 |
2017 Series D Common Stock Warrants to Placement Agent | |
Class of Warrant or Right [Line Items] | |
Exercise Price | $ / shares | $ 0.25 |
Term (Years) | 5 years |
Amount Vested and Outstanding | shares | 480,000 |
2017 Common Stock Warrants to Service Provider | |
Class of Warrant or Right [Line Items] | |
Exercise Price | $ / shares | $ 0.41 |
Term (Years) | 5 years |
Amount Vested and Outstanding | shares | 125,000 |
2018 Emerald Financing Warrants | |
Class of Warrant or Right [Line Items] | |
Exercise Price | $ / shares | $ 0.10 |
Term (Years) | 5 years |
Amount Vested and Outstanding | shares | 3,400,000 |
Emerald Multi-Draw Credit Agreement Warrants | |
Class of Warrant or Right [Line Items] | |
Exercise Price | $ / shares | $ 0.50 |
Term (Years) | 5 years |
Amount Vested and Outstanding | shares | 7,500,000 |
2019 Common Stock Warrants | |
Class of Warrant or Right [Line Items] | |
Exercise Price | $ / shares | $ 0.35 |
Term (Years) | 5 years |
Amount Vested and Outstanding | shares | 8,000,000 |
Warrants and Derivative Liabi_4
Warrants and Derivative Liabilities (Details 1) - Pricing Model - Emerald Multi-Draw Credit Agreement Warrants | Mar. 31, 2020Percent$ / shares |
Minimum | |
Class of Warrant or Right [Line Items] | |
Underlying common stock price | $ / shares | $ 0.33 |
Maximum | |
Class of Warrant or Right [Line Items] | |
Underlying common stock price | $ / shares | $ 0.69 |
Dividend yield | |
Class of Warrant or Right [Line Items] | |
Warrants and rights outstanding measurement input | 0 |
Volatility factor | Minimum | |
Class of Warrant or Right [Line Items] | |
Warrants and rights outstanding measurement input | 91.6 |
Volatility factor | Maximum | |
Class of Warrant or Right [Line Items] | |
Warrants and rights outstanding measurement input | 92.1 |
Risk-free interest rate | Minimum | |
Class of Warrant or Right [Line Items] | |
Warrants and rights outstanding measurement input | 2.23 |
Risk-free interest rate | Maximum | |
Class of Warrant or Right [Line Items] | |
Warrants and rights outstanding measurement input | 2.51 |
Expected term (years) | |
Class of Warrant or Right [Line Items] | |
Expected Term | 5 years |
Warrants and Derivative Liabi_5
Warrants and Derivative Liabilities (Details 2) - USD ($) | 3 Months Ended | |||
Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | |
Fair Value Of Derivative Liabilities [Roll Forward] | ||||
Fair Value of Derivative Liabilities | $ 501,400 | $ 15,958,366 | ||
Fair Value of Derivative Liabilities Issued | 0 | 516,058 | ||
Change in Fair value of Derivative Liabilities | (35,903) | 12,820,618 | ||
Reclassification of Derivatives to Equity | (26,563) | 0 | ||
Fair Value of Derivative Liabilities | 438,934 | 29,295,042 | ||
Less, noncurrent portion of derivative liabilities | (190,882) | (963,369) | $ (90,797) | $ (219,453) |
Current balance of derivative liabilities | 248,052 | 28,331,673 | $ 410,603 | $ 15,738,913 |
Emerald Multi-Draw Credit Agreement - compound derivative liability | ||||
Fair Value Of Derivative Liabilities [Roll Forward] | ||||
Fair Value of Derivative Liabilities | 90,797 | 219,453 | ||
Fair Value of Derivative Liabilities Issued | 0 | 516,058 | ||
Change in Fair value of Derivative Liabilities | 100,085 | 227,858 | ||
Reclassification of Derivatives to Equity | 0 | 0 | ||
Fair Value of Derivative Liabilities | 190,882 | 963,369 | ||
Series B Warrant Liability | ||||
Fair Value Of Derivative Liabilities [Roll Forward] | ||||
Fair Value of Derivative Liabilities | 134,579 | 487,500 | ||
Fair Value of Derivative Liabilities Issued | 0 | 0 | ||
Change in Fair value of Derivative Liabilities | (54,109) | 353,438 | ||
Reclassification of Derivatives to Equity | (26,563) | 0 | ||
Fair Value of Derivative Liabilities | 53,907 | 840,938 | ||
Emerald Financing - Warrant Liability | ||||
Fair Value Of Derivative Liabilities [Roll Forward] | ||||
Fair Value of Derivative Liabilities | 276,024 | 15,251,413 | ||
Fair Value of Derivative Liabilities Issued | 0 | 0 | ||
Change in Fair value of Derivative Liabilities | (81,879) | 12,239,322 | ||
Reclassification of Derivatives to Equity | 0 | 0 | ||
Fair Value of Derivative Liabilities | $ 194,145 | $ 27,490,735 |
Warrants and Derivative Liabi_6
Warrants and Derivative Liabilities (Details 3) - Monte Carlo simulations - Emerald Multi-Draw Credit Agreement - compound derivative liability | Mar. 31, 2020Percent$ / shares |
Class of Warrant or Right [Line Items] | |
Underlying common stock price | $ / shares | $ 0.08 |
Volatility factor | |
Class of Warrant or Right [Line Items] | |
Warrants and rights outstanding measurement input | 79.8 |
Benchmarked yield | |
Class of Warrant or Right [Line Items] | |
Warrants and rights outstanding measurement input | 18.46 |
Remaining term (years) | |
Class of Warrant or Right [Line Items] | |
Expected Term | 2 years 6 months 18 days |
Warrants and Derivative Liabi_7
Warrants and Derivative Liabilities (Details 4) - Monte Carlo simulations - Emerald Financing | Mar. 31, 2020Percent$ / shares | Dec. 31, 2019Percent$ / shares |
Class of Warrant or Right [Line Items] | ||
Underlying common stock price | $ / shares | $ 0.08 | $ 0.13 |
Dividend yield | ||
Class of Warrant or Right [Line Items] | ||
Warrants and rights outstanding measurement input | 0 | 0 |
Volatility factor | ||
Class of Warrant or Right [Line Items] | ||
Warrants and rights outstanding measurement input | 81.4 | 79.5 |
Risk-free interest rate | ||
Class of Warrant or Right [Line Items] | ||
Warrants and rights outstanding measurement input | 0.28 | 1.62 |
Expected term (years) | ||
Class of Warrant or Right [Line Items] | ||
Expected Term | 2 years 10 months 17 days | 3 years 1 month 17 days |
Warrants and Derivative Liabi_8
Warrants and Derivative Liabilities (Details 5) - Pricing Model - Series B warrant | Mar. 31, 2020Percent$ / shares | Dec. 31, 2019Percent$ / shares |
Class of Warrant or Right [Line Items] | ||
Underlying common stock price | $ / shares | $ 0.08 | $ 0.13 |
Dividend yield | ||
Class of Warrant or Right [Line Items] | ||
Warrants and rights outstanding measurement input | 0 | 0 |
Volatility factor | ||
Class of Warrant or Right [Line Items] | ||
Warrants and rights outstanding measurement input | 79.8 | 79.2 |
Risk-free interest rate | ||
Class of Warrant or Right [Line Items] | ||
Warrants and rights outstanding measurement input | 0.13 | 1.60 |
Expected term (years) | ||
Class of Warrant or Right [Line Items] | ||
Expected Term | 4 months 20 days | 7 months 20 days |
Warrants and Derivative Liabi_9
Warrants and Derivative Liabilities (Detail Textuals) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||
Feb. 16, 2018 | Jan. 19, 2018 | Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | Dec. 28, 2017 | |
Class of Warrant or Right [Line Items] | ||||||
Warrants issued in connection with convertible multi draw credit agreement related party value | $ 716,110 | |||||
Warrant vested aggregate fair value utilizing the Black-Scholes option pricing model | $ (35,903) | $ 12,820,618 | ||||
Emerald Financing Warrant Liability | ||||||
Class of Warrant or Right [Line Items] | ||||||
Total number of warrants issued | 44,200,000 | 44,200,000 | ||||
Warrant exercise price | $ 0.10 | $ 0.10 | ||||
Term of warrant | 5 years | 5 years | ||||
Aggregate exercise price of outstanding credit agreement | $ 4,080,000 | |||||
Emerald Multi-Draw Credit Agreement Warrants | ||||||
Class of Warrant or Right [Line Items] | ||||||
Number of warrants issued | 5,000,000 | |||||
Warrant exercise price | $ 0.50 | |||||
Term of warrant | 5 years | |||||
Warrants issued in connection with convertible multi draw credit agreement related party value | $ 716,110 | |||||
Emerald Multi-Draw Credit Agreement Warrants | Warrant | ||||||
Class of Warrant or Right [Line Items] | ||||||
Warrant vested aggregate fair value utilizing the Black-Scholes option pricing model | $ 1,830,573 | |||||
Series B Warrants | ||||||
Class of Warrant or Right [Line Items] | ||||||
Number of warrants issued | 312,500 | |||||
Value of common stock called by warrants | $ 26,563 | |||||
Total number of warrants issued | 312,500 | |||||
Warrant exercise price | $ 0 | $ 0.10 | ||||
Conversion price, per share (in dollars per share) | $ 0 | |||||
Series B Warrants | Warrant | ||||||
Class of Warrant or Right [Line Items] | ||||||
Warrant exercise price | $ 1.15 |
Convertible Debt - Related Pa_3
Convertible Debt - Related Party (Details) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Short-term Debt [Line Items] | ||
Less, noncurrent portion | $ (517,780) | $ (387,070) |
Convertible debt | Emerald Health Sciences Inc | ||
Short-term Debt [Line Items] | ||
Total principal value | 2,014,500 | 2,014,500 |
Unamortized debt discount | (1,491,997) | (1,622,344) |
Unamortized debt issuance costs | (4,723) | (5,086) |
Carrying value of total convertible debt - related party | 517,780 | 387,070 |
Less, noncurrent portion | (517,780) | (387,070) |
Current convertible debt - related party | $ 0 | $ 0 |
Convertible Debt - Related Pa_4
Convertible Debt - Related Party (Details 1) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Debt Disclosure [Abstract] | ||
Interest expense - stated rate | $ 35,645 | $ 59,111 |
Non-cash interest expense: | ||
Amortization of debt discount | 130,347 | 53,979 |
Amortization of transaction costs | 363 | 2,973 |
Interest Expense | $ 166,355 | $ 116,063 |
Convertible Debt - Related Pa_5
Convertible Debt - Related Party (Detail Textuals) - USD ($) | Nov. 01, 2018 | Nov. 01, 2018 | Oct. 05, 2018 | Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | Dec. 31, 2018 |
Debt Instrument [Line Items] | |||||||
Derivative liability | $ 438,934 | $ 29,295,042 | $ 501,400 | $ 15,958,366 | |||
Fair value of derivative liabilities in excess of proceeds | 322,644 | ||||||
Multi-Draw Credit Agreement | |||||||
Debt Instrument [Line Items] | |||||||
Warrants | 2,000,000 | ||||||
Aggregate Principal Amount | $ 4,000,000 | ||||||
Proceeds from related party debt | $ 2,000,000 | ||||||
Number of warrant issued | 2,500,000 | 2,500,000 | 5,000,000 | ||||
Allocation of debt on the basis of relative fair value | $ 1,684,920 | $ 1,684,920 | $ 3,283,890 | ||||
Allocation of warrant on the basis of relative fair value | 315,080 | 315,080 | 716,110 | ||||
Beneficial conversion feature | 90,080 | 1,584,850 | |||||
Derivative liability | $ 204,102 | $ 204,102 | 516,058 | ||||
Convertible multi-draw credit agreement issuance costs | $ 63,007 | ||||||
Proceeds from warrant exercises | 3,985,500 | ||||||
Loss on extinguishment of debt | 725,425 | ||||||
Unamortized debt discount period | 2 years 6 months 7 days | ||||||
Carrying value of the equity component | $ 377,719 | ||||||
Fair value of derivative liabilities in excess of proceeds | 322,644 | ||||||
Emerald Financing | |||||||
Debt Instrument [Line Items] | |||||||
Derivative liability | 194,145 | $ 27,490,735 | $ 276,024 | $ 15,251,413 | |||
Emerald Financing | Multi-Draw Credit Agreement | |||||||
Debt Instrument [Line Items] | |||||||
Maximum amount that can be borrowed over the life of the credit facility | $ 20,000,000 | ||||||
The annual stated interest rate on the debt instrument | 7.00% | ||||||
Maturity date | Oct. 5, 2022 | ||||||
Conversion price | $ 0.40 | ||||||
Unused portion of the credit facility | $ 14,000,000 | ||||||
Warrant coverage on the debt facility | 50.00% | ||||||
Warrant exercise price | $ 0.50 |
Stockholders' Deficit and Capit
Stockholders' Deficit and Capitalization (Detail Textuals) - $ / shares | Mar. 31, 2020 | Dec. 31, 2019 |
Equity [Line Items] | ||
Common stock, shares authorized | 500,000,000 | 500,000,000 |
Preferred stock (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 20,000,000 | 20,000,000 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Stock-Based Compensation (Detai
Stock-Based Compensation (Details) - Restricted stock awards | 3 Months Ended |
Mar. 31, 2020$ / sharesshares | |
Number of Shares | |
Unvested, December 31, 2019 | shares | 450,000 |
Granted | shares | 0 |
Released | shares | (450,000) |
Unvested, March 31, 2020 | shares | 0 |
Weighted Average Grant Date Fair Value | |
Unvested, December 31, 2019 | $ / shares | $ 0.19 |
Granted | $ / shares | 0 |
Released | $ / shares | 0.19 |
Unvested, March 31, 2020 | $ / shares | $ 0 |
Stock-Based Compensation (Det_2
Stock-Based Compensation (Detail Textuals) - shares | 1 Months Ended | 3 Months Ended |
Oct. 31, 2014 | Mar. 31, 2020 | |
Restricted stock awards | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Number of restricted common stock granted | 0 | |
Number of restricted common stock vested | 450,000 | |
Omnibus Incentive Plan 2014 | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Number of shares reserved for future grants | 13,159,631 | |
Omnibus Incentive Plan 2014 | Stock Option | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Number of shares reserved for future grants | 3,200,000 | |
Percentage of share reserve of the number of issued and outstanding shares | 10.00% |
Stock-Based Compensation (Det_3
Stock-Based Compensation (Detail Textuals 1) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Share-based Payment Arrangement [Abstract] | ||
Stock-based compensation expense | $ 64,142 | $ 171,493 |
Total amount of unrecognized compensation cost related to non-vested stock options | $ 248,264 | |
Recognized weighted average period | 1 year 8 months 26 days |
Significant Contracts - Unive_2
Significant Contracts - University of Mississippi (Detail Textuals) - USD ($) | Jan. 10, 2017 | Jul. 31, 2018 | Mar. 31, 2020 |
University Of Mississippi Agreements [Line Items] | |||
Annual maintenance fee payable | $ 75,000 | ||
UM 5050 pro-drug agreements | University of Mississippi | Intellectual Property | |||
University Of Mississippi Agreements [Line Items] | |||
Payment for upfront fees | $ 100,000 | ||
UM 8930 analogue agreements | University of Mississippi | Intellectual Property | |||
University Of Mississippi Agreements [Line Items] | |||
Payment for upfront fees | 200,000 | ||
Annual fees for license agreement | $ 200,000 | ||
UM 5070 license agreement | University of Mississippi | Intellectual Property | |||
University Of Mississippi Agreements [Line Items] | |||
Term of agreement | 1 year | ||
Notice period for termination | 60 days | ||
Aggregate milestone payments if milestones achieved | $ 700,000 | ||
Um 5050 Pro-Drug And Um 8930 Analog Agreements | University of Mississippi | Intellectual Property | Milestone 1 | |||
University Of Mississippi Agreements [Line Items] | |||
Term of agreement | 30 days | ||
Aggregate milestone payments if milestones achieved | $ 100,000 | ||
Um 5050 Pro-Drug And Um 8930 Analog Agreements | University of Mississippi | Intellectual Property | Milestone 2 | |||
University Of Mississippi Agreements [Line Items] | |||
Term of agreement | 30 days | ||
Aggregate milestone payments if milestones achieved | $ 200,000 | ||
Um 5050 Pro-Drug And Um 8930 Analog Agreements | University of Mississippi | Intellectual Property | Milestone 3 | |||
University Of Mississippi Agreements [Line Items] | |||
Term of agreement | 30 days | ||
Aggregate milestone payments if milestones achieved | $ 400,000 |
Related Party Matters (Detail T
Related Party Matters (Detail Textuals) - Independent contractor agreement - USD ($) | 1 Months Ended | 3 Months Ended | ||
Mar. 30, 2020 | Dec. 19, 2019 | Mar. 31, 2020 | Mar. 31, 2019 | |
Dr. Avtar Dhillon | ||||
Related Party Transaction [Line Items] | ||||
Monthly fee | $ 10,000 | |||
Monthly fee paid each month | 5,000 | |||
Monthly fee accruing from effective date | $ 5,000 | |||
Percentage of accrued consulting fees | 100.00% | |||
Percentage of bonus for accrued consulting fees | 10.00% | |||
Accrued expense under agreement | $ 33,871 | |||
Emerald Health Sciences Inc | ||||
Related Party Transaction [Line Items] | ||||
Initial term of agreement | 10 years | |||
Expense incurred under agreement | $ 150,000 | |||
Accrued expense under agreement | $ 7,032 |
Subsequent Events (Detail Textu
Subsequent Events (Detail Textuals) - Subsequent Event - USD ($) | 1 Months Ended | ||||||
Jul. 31, 2020 | Jun. 30, 2020 | May 31, 2020 | May 15, 2020 | Apr. 29, 2020 | Apr. 24, 2020 | Apr. 22, 2020 | |
Amended and Restated Multi-Draw Credit Agreement | |||||||
Subsequent Event [Line Items] | |||||||
Principal amount of credit facility | $ 20,000,000 | ||||||
Credit facility advances | $ 6,000,000 | ||||||
Credit facility advances per month | $ 150,000 | $ 150,000 | $ 150,000 | ||||
Warrant to purchase number of shares of Common Stock equal to dollar amount | $ 0.50 | ||||||
Price per share of common stock | 0.35 | ||||||
Reduced fixed conversion price of common stock | 0.25 | ||||||
Conversion price | $ 0.40 | ||||||
Capital Raise | $ 5,000,000 | ||||||
Interest rates per annum | 7.00% | ||||||
Maturity date | Oct. 5, 2022 | ||||||
Separation Agreement | Douglas Cesario | |||||||
Subsequent Event [Line Items] | |||||||
Payment in consideration for restrictive covenants in Separation Agreement | $ 125,000 | ||||||
Unvested stock options cancelled | 325,929 | ||||||
Paycheck Protection Program Promissory Note (PPP Note) | |||||||
Subsequent Event [Line Items] | |||||||
Principal amount of promissory Note | $ 116,700 | ||||||
Maturity period of promissory note | 2 years | ||||||
Interest rate | 1.00% | ||||||
Debt forgiveness, CARES Act, description | For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $100,000, prorated annually. Not more than 25% of the forgiveness amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages of employees with salaries of $100,000 or less annually are reduced by more than 25%. |